SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently seeing a massive surge fueled by sympathy momentum from Intel's strong earnings report and bullish analyst upgrades that highlight rising CPU demand in AI data centers. While the community remains deeply polarized between long-term bulls targeting higher valuations and skeptics warning of an overextended bubble, traders are actively debating the sustainability of this rapid upward move.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant market momentum driven by a strong earnings beat and positive forward guidance, fueling widespread discussion about a potential CPU renaissance in AI-driven data centers. While the community is actively debating the sustainability of this rapid re-rating and debating whether to take profits or hold for long-term growth, analysts are rapidly revising their price targets in response to the surge.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The community is actively debating the sustainability of the semiconductor sector's parabolic rally, with many traders using $SOXS as a tactical hedge against perceived overextension and AI-driven euphoria. Amidst heavy volume, market participants are split between those betting on a major blow-off top and others warning that the instruments structural decay makes it a dangerous hold during sustained periods of upward sector momentum.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz is trending following a significant jury verdict awarding the company hundreds of millions in damages against rival Papaya Gaming for the use of bots. While the community is actively debating the stock's potential for a massive squeeze or further volatility, investors remain focused on the potential for additional disgorgement rulings and the company's improved financial outlook.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing intense investor activity driven by a parabolic rally in the semiconductor sector, fueled by massive AI-driven infrastructure demand and consistent momentum that has kept the ETF trending higher. While many in the community are celebrating record gains and speculative targets, others are actively debating whether this represents a sustainable super-cycle or a dangerous bubble approaching a blow-off top.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is surging due to positive financial results and guidance that emphasize a strategic pivot into AI-driven data center infrastructure. The community is actively debating the sustainability of this sharp rally, with many traders discussing the potential for a continued momentum trade versus concerns that the stock may be overextended.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is capturing significant attention as investors weigh the potential of its oral Wegovy pill against Eli Lilly's recent market entry, with the company's new AI partnership with OpenAI further fueling hopes for accelerated drug discovery. Despite recent share price volatility, the community is actively debating the stock's valuation, dividend yield, and the long-term impact of evolving GLP-1 competitive dynamics.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense buying activity and high volume as investors react to confirmed purchase orders linked to Marvell Technologies and ongoing speculation about partnerships with major cloud hyperscalers. Community sentiment is overwhelmingly bullish, with many traders framing the recent price action as a structural breakout that is forcing short sellers to cover their positions.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending as retail and institutional investors debate whether the sector is experiencing a historic AI-driven bull run or a dangerous bubble fueled by speculative circular financing. While many community members highlight the ETF's aggressive momentum and its role as a market leader, skeptics are expressing concern over overvaluation, supply chain bottlenecks, and increasing data center project delays.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is rallying strongly following the company's strategic unveiling of its first AGI CPU, which marks a significant shift into in-house silicon design for data centers and heightened competition with major industry players. Investors are actively discussing the stock's transition from an IP licensor to a direct hardware competitor, while community sentiment remains split between excitement over the potential for massive AI-driven valuation expansion and concerns regarding the sustainability of the stock's high trading multiples.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ruffer LLP Invests $2.48 Million in Neurocrine Biosciences, Inc. $NBIX

Ruffer LLP purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the...

Zurcher Kantonalbank Zurich Cantonalbank Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 44.7% during the 4th quarter, according to its most recent filing with the...

Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital...

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $170.00

Leerink Partners raised their target price on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an "outperform" rating in a research note on Wednesday...

Belpointe Asset Management LLC Acquires Shares of 9,485 Neurocrine Biosciences, Inc. $NBIX

Belpointe Asset Management LLC acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 9,485 shares of the company's stock, valued at appr...

3 Reasons Growth Investors Will Love Neurocrine (NBIX)

Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.

Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a Bet

The consensus price target hints at a 38.8% upside potential for Neurocrine (NBIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

KBC Group NV Has $4.60 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX

KBC Group NV boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 122.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,401 shares of the company's stock after...

Fortis Capital Advisors LLC Invests $1.35 Million in Neurocrine Biosciences, Inc. $NBIX

Fortis Capital Advisors LLC bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to its most recent disclosure with the...

Cwm LLC Purchases 11,306 Shares of Neurocrine Biosciences, Inc. $NBIX

Cwm LLC boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 95,030 shares of the company's stock after acquiring a...

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

NBIX
Neurocrine Biosciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NBIX News

NBIXNeurocrine Biosciences, Inc.